Matt graduated from UCL in 2017 with a bachelor’s degree in Biochemistry. He subsequently obtained a master’s degree entitled ‘Cellular Therapy from Bench to Market’, a program which blended biology and business to explore the science, regulation and routes to market underpinning advanced therapies. His thesis was a business plan to commercialise a stem cell-derived therapy for Parkinson’s disease. Following this, Matt joined the Cell and Gene Therapy Catapult as a laboratory technician gaining experience in ddPCR, cell culture, non-viral gene editing techniques, flow cytometry, as well as upstream and downstream processing of AAV (viral vector) for gene therapy applications.
Matt joined Keltie in 2022 following three years training at another leading patent law firm. He is part-qualified and working towards European and UK qualification.
Matt particularly enjoys working closely with clients to understand not only the detail behind their technology, but the business needs behind their intellectual property. He has experience in both drafting and prosecution, advising multinational pharmaceutical clients and early-stage spin-outs in a range of fields including antibodies, cell and gene therapies, small molecules and nanotechnologies.